药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Arformoterol
Fendiline
The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Fendiline.
Arformoterol
Bedaquiline
The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Bedaquiline.
Arformoterol
Fluspirilene
The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Fluspirilene.
Arformoterol
Prenylamine
The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Prenylamine.
Arformoterol
Dexchlorpheniramine
The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Dexchlorpheniramine.
Arformoterol
Lorcainide
The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Lorcainide.
Arformoterol
Bunaftine
The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Bunaftine.
Arformoterol
Nizofenone
The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Nizofenone.
Arformoterol
Sultopride
The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Sultopride.
Arformoterol
Sitafloxacin
The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Sitafloxacin.
Arformoterol
Oxatomide
The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Oxatomide.
Arformoterol
Abexinostat
The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Abexinostat.
Arformoterol
Mizolastine
The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Mizolastine.
Arformoterol
Ricolinostat
The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Ricolinostat.
Arformoterol
Simendan
The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Simendan.
Arformoterol
CUDC-101
The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with CUDC-101.
Arformoterol
Entinostat
The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Entinostat.
Arformoterol
Mocetinostat
The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Mocetinostat.
Arformoterol
Amifampridine
The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Amifampridine.
Arformoterol
Melperone
The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Melperone.